Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint [Yahoo! Finance]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Yahoo! Finance
Phase IIb/III registrational program (72-patient Phase IIb transitioning into ~270-patient Phase III) using an IGA 0/1 primary endpoint and targets an estimated U.S. patient population of up to ~100,000. Strong biological rationale for brepocitinib in LPP — Priovant and Roivant cite biomarker and investigator data showing JAK1/TYK2 inhibition suppresses Th1 cytokines (interferon-?, IL-12) and related chemokines, supporting a mechanistic fit and prior clinical signals in Th1-driven skin diseases. Batoclimab failed its Phase III TED primary endpoint — Roivant will not continue TED development with that molecule, pivoting to IMVT-1402 and ongoing Graves' studies after observing promising IgG suppression and responder signals in a small hyperthyroid subset, with Graves readouts expected next year. Interested in Roivant Sciences Ltd.? Here are five stocks we like better. Trump Index: 6 Companies Linked to Trump's Cabinet Worth Watching Roivant Sciences (NASDAQ:ROIV) outlined plan
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Ohio governor: Vivek Ramaswamy faces little-known GOP challengers [USA TODAY]USA TODAY
- Should Brepocitinib's New Trials and Batoclimab's Setback Require Action From Roivant Sciences (ROIV) Investors? [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update Transcript [Seeking Alpha]Seeking Alpha
- Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript [Seeking Alpha]Seeking Alpha
- Immunovant falls on late-stage trial setback for TED therapy [Seeking Alpha]Seeking Alpha
ROIV
Earnings
- 2/6/26 - In-Line
ROIV
Sec Filings
- 4/10/26 - Form 4
- 4/8/26 - Form 144
- 4/2/26 - Form 4
- ROIV's page on the SEC website